Hearing loss and its association with all-cause and cause-specific mortality: A meta-analysis of cohort studies
Abstract
Background: This study aimed to examine the epidemiological associations between hearing loss and the risk of all-cause mortality, cardiovascular mortality, and cancer mortality.
Methods: A comprehensive search was performed in PubMed, Cochrane Library, and Embase for cohort studies published from database inception to January 12, 2025, using relevant MeSH terms and keywords. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). A random-effects model was applied for the meta-analysis. Sensitivity analysis was conducted by sequentially excluding individual studies to assess the robustness of the results. Subgroup analyses were performed based on hearing function measurement methods, study design, and continent. Publication bias was evaluated using funnel plots and Egger's test. Statistical analyses were conducted using Stata 14.0.
Results: This meta-analysis included 36 cohort studies with a total of 6,364,914 participants, published between 1992 and 2024. Hearing loss was significantly associated with all-cause mortality (HR: 1.21; 95% CI: 1.13-1.31; I² = 95.7%, P < 0.001), cardiovascular mortality (HR: 1.22; 95% CI: 1.12-1.33; I² = 52.4%, P < 0.001), and cancer mortality (HR: 1.11; 95% CI: 1.02-1.22; I² = 51.2%, P = 0.016), after adjusting for demographics and comorbidities. Subgroup analysis showed that audiometrically measured hearing loss had a stronger effect than self-reported hearing loss (HR: 1.28; 95% CI: 1.10-1.49; I² = 97.7%, P = 0.002). The risk of…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 6,364,914 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.